Brigden D, Rosling A E, Woods N C
Am J Med. 1982 Jul 20;73(1A):182-5. doi: 10.1016/0002-9343(82)90087-0.
Plasma urea or creatinine was noted to be raised in 58 of 354 patients treated with intravenous acyclovir. This occurred after intravenous bolus injection of high dosages of acyclovir but the risk was considerably reduced by slow intravenous infusion of the same dosage over one hour, with adequate hydration of the patient and adjustment of dosage in patients with preexisting impaired renal function. Animal studies indicate that the impairment of renal function associated with high bolus injections of acyclovir is due to crystal formation in the renal tubules and/or the collecting ducts, and that the crystals are removed after cessation of treatment. The special problems involved in the treatment of patients with herpes encephalitis necessitating limited fluid intake and the possible interaction with other nephrotoxic drugs are discussed.
在354例接受静脉注射阿昔洛韦治疗的患者中,有58例患者的血浆尿素或肌酐水平升高。这一情况发生在静脉推注高剂量阿昔洛韦之后,但通过在一小时内缓慢静脉输注相同剂量的阿昔洛韦、使患者充分水化以及对已有肾功能损害的患者调整剂量,风险可显著降低。动物研究表明,高剂量推注阿昔洛韦导致的肾功能损害是由于肾小管和/或集合管中形成晶体,且在治疗停止后晶体会被清除。文中讨论了治疗疱疹性脑炎患者时因需要限制液体摄入而涉及的特殊问题以及与其他肾毒性药物可能存在的相互作用。